Bio­Marin lands three-year deal for Ger­man cov­er­age of gene ther­a­py at $900K per pa­tient

Bio­Marin an­nounced a new three-year deal on Tues­day with the Ger­man Na­tion­al As­so­ci­a­tion of Statu­to­ry Health In­sur­ance Funds (GKV-SV), which cov­ers about 90% of the Ger­man pop­u­la­tion, for re­im­burse­ment of its gene ther­a­py Roc­ta­vian (val­oc­toco­gene rox­a­parvovec-rvox) for pa­tients with se­vere he­mo­phil­ia A.

The Cal­i­for­nia-based com­pa­ny said its one-time, sin­gle-dose ther­a­py de­liv­ered via in­tra­venous in­fu­sion over three to four hours will have a gross price of €28,933.53 (about $31,780) per vial in Ger­many. That trans­lates to about $900,000 in net rev­enue per pa­tient for Bio­Marin at the cur­rent ex­change rate, the com­pa­ny said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA